K Spaepen

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. ncbi request reprint Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
    K Spaepen
    Departments of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    Ann Oncol 13:1356-63. 2002
  2. ncbi request reprint Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    K Spaepen
    Department of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    Br J Haematol 115:272-8. 2001
  3. ncbi request reprint Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    K Spaepen
    Department of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    J Clin Oncol 19:414-9. 2001
  4. doi request reprint Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET
    G Moulin-Romsee
    Department of Nuclear Medicine, KU Leuven, UZ Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium
    Eur J Nucl Med Mol Imaging 35:1074-80. 2008
  5. ncbi request reprint Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease
    K Spaepen
    Department of Nuclear Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Q J Nucl Med 45:269-73. 2001

Detail Information

Publications5

  1. ncbi request reprint Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
    K Spaepen
    Departments of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    Ann Oncol 13:1356-63. 2002
    ..This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL...
  2. ncbi request reprint Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    K Spaepen
    Department of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    Br J Haematol 115:272-8. 2001
    ..Two-year actuarial PFS rate for negative patients was 91% compared with 0% for positive patients. We concluded that [(18)F]-FDG-PET has an important prognostic role in the post-treatment evaluation of HD patients...
  3. ncbi request reprint Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    K Spaepen
    Department of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    J Clin Oncol 19:414-9. 2001
    ..In this study, we evaluated the value of PET in detecting residual disease and, hence, predicting relapse after first-line treatment in patients with non-Hodgkin's lymphoma (NHL)...
  4. doi request reprint Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET
    G Moulin-Romsee
    Department of Nuclear Medicine, KU Leuven, UZ Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium
    Eur J Nucl Med Mol Imaging 35:1074-80. 2008
    ..We investigated the costs and benefits for the use of PET in this early treatment setting...
  5. ncbi request reprint Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease
    K Spaepen
    Department of Nuclear Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Q J Nucl Med 45:269-73. 2001
    ..Finally, a strategy for the implementation of [18F]FDG-PET in the management of lymphoma patients is proposed...